Navigation Links
Little Evidence of Heart Risks From ADHD Meds
Date:11/1/2011

By Amanda Gardner
HealthDay Reporter

TUESDAY, Nov. 1 (HealthDay News) -- Medications commonly used to treat attention-deficit/hyperactivity disorder don't appear to raise the risk of heart attacks and other cardiovascular problems in children and young adults, new research shows.

And if any increased risk from stimulants such as Ritalin, Adderall and Concerta does exist, the danger in absolute numbers would be extremely low, said Dr. William O. Cooper, lead author of a study published online Nov. 1 in the New England Journal of Medicine.

"This is the largest study to date, and I feel this provides reassuring information about risk," said Cooper, a professor of pediatrics and preventive medicine at Vanderbilt University in Nashville, Tenn.

Another expert agreed. "This is really good information because a few years ago when we had the notifications coming out telling us to use these drugs with some caution, we didn't really have any good guidelines on which patients should avoid the drugs," said Dr. John Pliska, assistant professor of pediatrics at Texas A&M Health Science Center College of Medicine and chief of pediatric cardiology at Scott & White in Temple, Texas.

Almost 3 million children in the United States take prescription medications for attention-deficit/hyperactivity disorder (ADHD) each year. Children with the neurobehavioral disorder have excessive levels of activity, inattention and impulsiveness.

For the typical child diagnosed with the disorder, "if ADHD medications appear to be an important part of a treatment regimen, the worry about these cardiac risks should certainly be less," Cooper continued. "Having said that, it's really important that each child be evaluated by his or her health care provider to decide if it makes sense."

Several years ago, a few reports of sudden death, heart attacks and stroke among users raised concern among parents and health care providers about the safety of these medications, which are prescribed to help children focus and manage their behavior.

Canadian health authorities briefly removed Adderall from the market in 2005, and the U.S. Food and Drug Administration (FDA) required that ADHD drugs carry a "black box" label warning and a patient guide.

Subsequently, the American Heart Association stated it would be "reasonable" to give kids screening electrocardiograms before starting them on stimulant medication.

"This really added to the concern and confusion among families and health care providers," Cooper said.

To try to settle the question, Cooper and his colleagues analyzed data on 1.2 million children and young adults aged 2 to 24 enrolled in four large health plans around the United States. This was called a meta-analysis.

"We compared those currently using ADHD medicines to those not using these medications to look at their risk for sudden death, heart attack and stroke," Cooper explained. The medications included methylphenidate (Ritalin, Concerta), dexmethylphenidate (Focalin), dextroamphetamine (Dexedrine), amphetamine salts (Adderall), atomoxetine (Strattera) and pemoline (Cylert).

The authors concluded that there was really no raised risk of heart problems with these medications, although they also acknowledged the possibility of up to an 85 percent increased risk.

That's because the large size of the study and the rarity of events made it difficult to track the relative increased risk.

"Placing that in context, even if there was a doubling, the absolute risk would be very, very low," Cooper said.

The findings are similar to several reports published after the FDA's safety review was compiled, the authors said.

For his part, Pliska said EKGs [electrocardiograms] might still be helpful in identifying some children with cardiac defects.

And Cooper agreed that some children may have underlying heart disease or other problems that could potentially place them at risk. "We would need to think about their individual risk," he said, "but on a population level, this [study] suggests there is no increased risk."

Dr. Howard S. Weintraub, clinical director of the Center for the Prevention of Cardiovascular Disease at NYU Langone Medical Center in New York City, agreed that the data should allay fears about the drugs' safety.

The findings indicate that "when these medicines are appropriately utilized and kids are screened appropriately, there is no increased risk," Weintraub said.

"This is a large trial that scrutinizes the lives of a lot of young kids," he said. "The only issues are that the population was from a Medicaid basis so it may be a little different from how some other people are treated but, if anything, you would expect them to be at greater risk."

Although there's no longer a universal mandate for EKG screening in children considering stimulant drugs for ADHD, they "should still be screened for risk factors such as family history of sudden unexplained cardiac death, a child history of unexplained seizures or congenital heart disease," said Dr. Andrew Adesman, chief of developmental and behavioral pediatrics at the Steven and Alexandra Cohen Children's Medical Center of New York in New Hyde Park.

He added that the results of the new study "hopefully provide further reassurance to parents and professionals that stimulant medications don't pose a significant cardiovascular risk."

More information

The U.S. National Institute of Mental Health has more on ADHD.

SOURCES: William O. Cooper, M.D., M.P.H., professor of pediatrics and preventive medicine, Vanderbilt University, Nashville, Tenn.; John Pliska, M.D., assistant professor of pediatrics, Texas A&M Health Science Center College of Medicine, and chief of pediatric cardiology, Scott & White, Temple, Texas; Howard S. Weintraub, M.D., clinical director, Center for the Prevention of Cardiovascular Disease, NYU Langone Medical Center, New York City; Andrew Adesman, M.D., chief, developmental and behavioral pediatrics, Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park; Nov. 1, 2011, New England Journal of Medicine, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. For Valentine's Day, Lifestyle Correspondent and Her Two Sets of Twins Show a Little Love Where Its Needed the Most
2. Reno Children With Disabilities Profit From a Little Known but Internationally Recognized Non-Profit Organization as it Quietly Crosses the $200,000.00 Mark in Service Investment Into the Reno Area
3. Secretary Clintons Approach to Development: Good Rhetoric, Little Action?
4. Experts Say Its Not So Bad to Go a Little Mad
5. Little City Foundation Battles for Rights of Individuals with Disabilities in Springfield and Meets with Legislators Day Before Governors Budget Address
6. Newer Genetic Info Adds Little to Predicting Breast Cancer
7. Low-Fat Diet Does Little to Alter Cholesterol Levels
8. A Little Chocolate May Do the Heart Good
9. Anti-aging hormones: Little or no benefit and the risks are high
10. Registration Now Open for Little Red Door's Unite 2 Fight Race Against Prostate Cancer Saturday, July 10, 2010
11. Clifford Power Systems, Inc. Celebrates 25th Anniversary with 7th location in Little Rock, Arkansas
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Little Evidence of Heart Risks From ADHD Meds
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
(Date:6/24/2016)... ... 2016 , ... People across the U.S. are sharpening their pencils and honing ... contest in which patients and their families pay tribute to a genetic counselor by ... Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
Breaking Medicine Technology: